Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vor Biopharma ( (VOR) ) has provided an announcement.
On December 5, 2025, Vor Biopharma‘s board approved a stock option repricing, reducing the exercise price of certain options to $8.18 per share to align with the market value on that date. This decision aims to retain and motivate employees by making their options more attractive without incurring additional equity or cash costs, impacting approximately 5.2 million shares. The repricing includes options held by key executives, such as CEO Jean-Paul Kress, and involves a retention period until December 5, 2027, or other specified conditions. Additionally, CFO Sandy Mahatme’s restricted stock units were replaced with an option to purchase 1,388,274 shares, with similar repricing terms.
The most recent analyst rating on (VOR) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company is engaged in advancing its pipeline of engineered hematopoietic stem cells and other related products to address unmet medical needs in oncology.
Average Trading Volume: 626,481
Technical Sentiment Signal: Sell
Current Market Cap: $179.2M
For detailed information about VOR stock, go to TipRanks’ Stock Analysis page.